Zeiss introduces new automated microscopy platform

Share

Zeiss CelldiscovererCarl Zeiss Microscopy recently announced a new system for automated microscopy in life sciences research.

Zeiss’s Celldiscoverer 7 combines the user-friendly automation features of a boxed microscope with the image quality and flexibility of a classic inverted research microscope, according to the company. Scientists acquire better data in shorter times with 2D or 3D cell cultures, tissue sections or small model organisms.

In contrast to other boxed microscopes with limited flexibility, Zeiss Celldiscoverer 7 can be adapted to a whole range of tasks and applications. The system comes with various incubation and detection options and can be tailored to the individual needs of research labs. Users can choose from a selected range of microscope cameras for even the most demanding live cell experiments and rapid time-lapse recordings. In particular, the new Zeiss Axiocam 512 mono microscope camera with highest 12 MP resolution and a large field of view allows fluorescence screening applications with high throughput.

The new optical design of Zeiss Celldiscoverer 7 together with advanced automatic calibration routines helps researchers to achieve reproducible high-quality data even from complex long-term, time-lapse imaging experiments. A new hardware-based autofocus not only finds and keeps the focus automatically, but also detects the thickness and optical properties of the sample carrier. This information is then used to adapt the unique Zeiss Autocorr objectives to deliver the best image quality possible.

Zeiss’s Celldiscoverer 7 is controlled by Zen imaging software that provides additional key features for the automated microscope system. The dedicated software package from Zeiss, for example, calculates the maximal scanning area for any sample carrier automatically and actively protects the objective from collisions with your sample vessel or other hardware components.

Carl Zeiss Microscopy

www.zeiss.com/microscopy/us/home.html

 

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*